Product Name | Kenpaullone |
Description |
GSK3Beta,CDK2 and LCK Inhibitor |
Purity | >98% (HPLC); NMR (conforms) |
CAS No. | 142273-20-9 |
Molecular Formula | C16H11BrN2O |
Molecular Weight | 327.2 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | May be dissolved in DMSO (35 mg/ml) |
Source | Synthetic |
Appearance | Beige powder |
SMILES | C1C2=C(C3=CC=CC=C3NC1=O)NC4=C2C=C(C=C4)Br |
InChI | InChI=1S/C16H11BrN2O/c17-9-5-6-14-11(7-9)12-8-15(20)18-13-4-2-1-3-10(13)16(12)19-14/h1-7,19H,8H2,(H,18,20) |
InChIKey | QQUXFYAWXPMDOE-UHFFFAOYSA-N |
Safety Phrases |
Classification: Caution: Substance not yet fully tested. Safety Phrases: S22 - Do not breathe dust S24/25 - Avoid contact with skin and eyes S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection |
Cite This Product | Kenpaullone (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-598) |
Alternative Names | 9-Bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one; NSC-664704 |
Research Areas | Apoptosis, Cancer, Cdks, Cell Signaling, Protein Phosphorylation, Serine / Threonine Kinases |
PubChem ID | 3820 |
Scientific Background | Kenpaullone is a potent inhibitor of cyclin-dependent kinases (CDKs) such as CDK2 and CDK5, as well as casein kinase 1 (CK1) and glycogen synthase kinase 3 beta (GSK3β). These kinases are involved in cell cycle regulation, apoptosis, and tau phosphorylation. In neurodegenerative disease research, Kenpaullone is studied for its ability to inhibit aberrant kinase activity associated with Alzheimer’s disease and other tauopathies. By modulating key signaling pathways, Kenpaullone may help prevent neuronal death and protein aggregation, offering potential neuroprotective benefits. |
References | 1. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/kenpaullone |
Reviews
There are no reviews yet.